Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sonus Pharma (SNUS) ? Opinions -- Ignore unavailable to you. Want to Upgrade?

To: (no name provided) who wrote (276)	3/30/1998 4:26:00 PM
From: Boyce Burge	Respond to of 384

The Dow Jones news service reports today rumors that there will be a positive European review of Echogen... word could come tomorrow. Volume is almost 700,000 today, 26 1/2 the high. Whether its approved for one indication or several, approval will clearly signal that Echogen seen as safe and useful by 15 European countries. The size of the market is a mystery... always an issue with a new drug or chemical entity... it would be good to hear from a real live radiologist on the prospects for Echogen, once approved. For now I'll have to rely on the hefty Abbott payments to Sonus as an indicator of probable market size, since Abbott would do nothing without a thorough and thoughtful market survey. To my way of thinking the Sonus story is intact. They will meet with the FDA on April 27th, a generaly positive sign. European approval won't force approval by the FDA, but the real valuation issues to me are market size and patent issues, not ultimate FDA approval.